Greg Bertenshaw is currently the Director of Translational Medicine Strategy for Early Oncology at AstraZeneca. They previously held the position of Vice President of R&D at BioMarker Strategies, where they developed innovative cancer diagnostic systems. Their extensive experience includes Director roles at Clearant Inc and Correlogic Systems, Inc., contributing to biomarker panel discovery and in vitro diagnostic tests. Greg earned a PhD in Biochemistry & Molecular Biology from Pennsylvania State University College of Medicine, having completed their undergraduate studies at The University of Manchester.
This person is not in the org chart
This person is not in any teams
This person is not in any offices